2016 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases: Effects of abaloparatide on vertebral, nonvertebral, major osteoporotic and clinical fracture incidence in postmenopausal women with osteoporosis: result of the phase 3 ACTIVE trial

2463 postmenopausal women with osteoporosis were randomized to one of three groups: daily subcutaneous abaloparatide (80ug), daily subcutaneous teriparatide (20ug), or daily subcutaneous placebo. The treatment period was 18 months, and patients were assessed for bone mineral density and incident fracture rate. Abaloparatide treatment was reported to result in a significantly greater increase in bone mineral density of the femoral neck and total hip after 18 months compared to both teriparatide and placebo. Both the abaloparatide and teriparatide treatments demonstrated a reduction in vertebral fracture risk, though a reduction in nonvertebral fracture risk was only significant for abaloparatide versus placebo. Risk reduction of major osteoporotic fracture was significant for abaloparatide versus both placebo and teriparatide. Adverse events were reported to be similar between groups.